Literature DB >> 29431050

TDP-43 post-translational modifications in health and disease.

Emanuele Buratti1.   

Abstract

INTRODUCTION: Nuclear factor TDP-43 is a ubiquitously expressed RNA binding protein that plays a key causative role in several neurodegenerative diseases, especially in the ALS/FTD spectrum. In addition, its aberrant aggregation and expression has been recently observed in other type of diseases, such as myopathies and Niemann-Pick C, a lysosomal storage disease. Areas covered: This review aims to specifically cover the post-translational modifications (PTMs) that can affect TDP-43 function and cellular status both in health and disease. To this date, these include phosphorylation, formation of C-terminal fragments, disulfide bridge formation, ubiquitination, acetylation, and sumoylation. Recently published articles on these subjects have been reviewed in this manuscript. Expert opinion: Targeting aberrant TDP-43 expression in neurodegenerative diseases is a very challenging task due to the fact that both its overexpression and downregulation are considerably toxic to cells. This characteristic makes it difficult to therapeutically target this protein in a generalized manner. An alternative approach could be the identification of specific aberrant PTMs that promote its aggregation or toxicity, and developing novel therapeutic approaches toward their selective modification.

Entities:  

Keywords:  ALS; FTLD; IBM; NPC; TDP-43; post-translational modifications

Mesh:

Substances:

Year:  2018        PMID: 29431050     DOI: 10.1080/14728222.2018.1439923

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  45 in total

1.  Dysregulation of TDP-43 intracellular localization and early onset ALS are associated with a TARDBP S375G variant.

Authors:  Kathy Newell; Francesca Paron; Miguel Mompean; Jill Murrell; Elisa Salis; Cristiana Stuani; Gary Pattee; Maurizio Romano; Douglas Laurents; Bernardino Ghetti; Emanuele Buratti
Journal:  Brain Pathol       Date:  2018-12-27       Impact factor: 6.508

2.  Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43).

Authors:  Friederike Hans; Marita Eckert; Felix von Zweydorf; Christian Johannes Gloeckner; Philipp J Kahle
Journal:  J Biol Chem       Date:  2018-08-17       Impact factor: 5.157

3.  Targeting TDP-43 Pathology Alleviates Cognitive and Motor Deficits Caused by Chronic Cerebral Hypoperfusion.

Authors:  Sai Sampath Thammisetty; Laurence Renaud; Vincent Picher-Martel; Yuan Cheng Weng; Frédéric Calon; Stephan Saikali; Jean-Pierre Julien; Jasna Kriz
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

4.  TDP-43 and NOVA-1 RNA-binding proteins as competitive splicing regulators of the schizophrenia-associated TNIK gene.

Authors:  Valentina Gumina; Claudia Colombrita; Claudia Fallini; Patrizia Bossolasco; Anna Maria Maraschi; John E Landers; Vincenzo Silani; Antonia Ratti
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-08-02       Impact factor: 4.490

5.  Huntington's disease mice and human brain tissue exhibit increased G3BP1 granules and TDP43 mislocalization.

Authors:  Isabella I Sanchez; Thai B Nguyen; Whitney E England; Ryan G Lim; Anthony Q Vu; Ricardo Miramontes; Lauren M Byrne; Sebastian Markmiller; Alice L Lau; Iliana Orellana; Maurice A Curtis; Richard Lewis Maxwell Faull; Gene W Yeo; Christie D Fowler; Jack C Reidling; Edward J Wild; Robert C Spitale; Leslie M Thompson
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

6.  Frontotemporal Lobar Degeneration TDP-43-Immunoreactive Pathological Subtypes: Clinical and Mechanistic Significance.

Authors:  Manuela Neumann; Edward B Lee; Ian R Mackenzie
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Trends in Understanding the Pathological Roles of TDP-43 and FUS Proteins.

Authors:  Emanuele Buratti
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Post-translational Control of RNA-Binding Proteins and Disease-Related Dysregulation.

Authors:  Alejandro Velázquez-Cruz; Blanca Baños-Jaime; Antonio Díaz-Quintana; Miguel A De la Rosa; Irene Díaz-Moreno
Journal:  Front Mol Biosci       Date:  2021-04-27

Review 9.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

Review 10.  Regulation of Neurodegeneration-associated Protein Fragments by the N-degron Pathways.

Authors:  Mohamed A Eldeeb; Mohamed A Ragheb; Marwa H Soliman; Richard P Fahlman
Journal:  Neurotox Res       Date:  2022-01-18       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.